Introduction

History and early virological studies
Abelson and Rabstein isolated the acute transforming retrovirus, Abelson Murine Leukemia Virus (AMuLV) in 1970 while studying Moloney murine leukemia virus (Mo-MuLV)-induced tumors in athymic mice. In this study, one of the 153 mice infected with Mo-MuLV three developed an unusual lymphosarcoma after a 3 month period (Abelson and Rabstein, 1970a,b) . This single animal exhibited multiple tumors of the lymph nodes with bone marrow infiltration, particularly in the cranium. The original tumor was transplanted, and filtered extracts of both the original tumor and of the transplants induced tumors rapidly upon injection into newborn or adult BALB/c mice (Rabstein et al., 1971; Siegler et al., 1972) . That the thymus in these animals was normal in all instances indicated that the transforming principle was something other than Mo-MuLV, a virus with a well-characterized thymus tropism (Moloney, 1960) . Transplanted A-MuLV-induced tumors were analysed for surface markers, and immunoglobulin (Ig) heavy chain was observed in all the tumors analysed. The finding that A-MuLV tumor cell lines synthesize membrane bound Ig identified Blymphocytes as the A-MuLV target cells (Premkumar et al., 1975) . This finding was confirmed by transformation studies in vitro.
In 1975, Scher and Siegler were the first to demonstrate that the extracts prepared from A-MuLVinduced tumors were capable of transforming murine fibroblasts in vitro. They isolated transformed NIH3T3 cell lines which did not produce Mo-MuLV particles, thereby demonstrating A-MuLV to be a replication defective acute transforming retrovirus (Scher and Siegler, 1975) . A soft-agar transformation system developed for lymphoid cells revealed that cells isolated from any lymphoid tissue including those derived from the bone marrow were susceptible to A-MuLV-mediated transformation (Rosenberg and Baltimore, 1976) . In A-MuLV transformation studies performed in vitro, lymphoid cells were transformed with 10 -100-fold greater efficiency than fibroblasts (Rosenberg and Baltimore, 1976) . Molecular studies later identified common signaling pathways involved in both fibroblast and lymphoid transformation. The basis for the greater susceptibility of lymphoid cells for transformation by A-MuLV, however, remains unknown.
Early characterization of individual A-MuLV isolates revealed a series of immunologically-related protein products whose sizes ranged from 90 -160 kD . These findings suggested that a portion of the AMuLV genome was dispensible for transformation since all of the recovered isolates were able to transform cells in vitro. Early molecular characterization of the A-MuLV genome revealed that it was generated through the recombination of Mo-MuLV with the murine c-abl proto-oncogene (Figure 1 ). This recombination event generated a fusion gene consisting of Mo-MuLV gag and endogenous murine c-abl sequences (Goff et al., 1980; Srinivasan et al., 1981; Reddy et al., 1983) which was named v-abl. Witte et al. (1979 Witte et al. ( , 1980 were the first to demonstrate the biochemical activity of the v-abl gene product. In these studies, P120
v-abl was shown to both phosphorylate itself as well as exogenous substrates on tyrosine residues. The transforming activity of A-MuLV was later found to be dependent on v-abl kinase activity both in lymphoid cell and in fibroblasts Srinivasan et al., 1982; Prywes et al., 1983) .
Analysis of the nucleotide and amino acid sequence of the c-abl gene revealed functional domains separable from the kinase domain, many of which serve to integrate the protein into signal transduction pathways (Oppi et al., 1987) . These include a proline-rich region, as well as src homology 2 (SH2) and SH3 domains, which allow the abl gene to be included with members of the src family of protein tyrosine kinases (PTKs). An actin-binding region has also been identified at the extreme C-terminus c-abl. This domain distinguishes Abl proteins from other members of the src family PTKs. Some of the c-Abl encoded domains such as the SH3 domain may be non-functional in v-Abl due to recombination-associated deletion of SH3 coding sequences during generation of A-MuLV (Wang, 1993) .
v-Abl gene and gene product
Sequence analysis of A-MuLV revealed the open reading frame (ORF) that encodes the 120 kD v-Abl protein (Reddy et al., 1983) . This ORF contains 5' and 3' sequences common to Mo-MuLV and internal sequences homologous to the c-abl gene. The v-abl gag fusion gene is comprised of 219 codons of MoMuLV sequence including the ORFs encoding p12 gag , p15 gag , and 21 amino acids from p30 gag . The v-Abl protein also contains 678 c-abl specific codons. A second open reading frame was identified as well, encoding a putative 18 kD protein. The A-MuLV genome that encodes the 160 kD protein (P160 v-abl ) was also cloned. Sequence comparison between P160 and P120 revealed that P120 lacked 263 amino acids due to an in-frame deletion of 789 base pairs of abl coding sequence. The Mo-MuLV/c-abl sequence junctions in P160 v-abl are identical to those in P120 v-abl , as is the presence of the 3' open reading frame that encodes the 18 kD polypeptide. The 5' recombination site is thought to involve a 4 bp homology between gag and c-abl (5' TACA 3') while the mechanism of the 3' recombination is unknown (Reddy et al., 1980; Latt et al., 1983; Wang et al., 1984; Oppi et al., 1987) . That the two A-MuLV strains, P120 and P160 possess identical Mo-MuLV recombination sites suggests they were the original viruses, with P120 originating from P160. The similarity of transcript size among the various v-Abl mutants suggests that the altered gene products arose subsequently, and due to mutations. This is the case for P90 v-abl in which a frame shift introduces a premature termination codon .
Following the cloning and sequencing of the murine c-abl gene, it became possible to compare the v-abl and c-abl sequences (Oppi et al., 1987) . Such comparison (Wang et al., 1984; Oppi et al., 1987) . The 5' end of the c-abl gene is encoded by alternative exons, types 1 -4, (BenNeriah et al., 1986 ) each of which is spliced to the common exon 2, thus generating four unique c-abl mRNAs. The 5' recombination site in A-MuLV genome interrupts c-abl exon 3 (Wang et al., 1984 and Figure 1 ) resulting in the loss of coding sequence from c-abl exons 1 and 2. Since the SH3 domain of cAbl is encoded by exon 2, the v-Abl protein lacks this important interaction domain. In addition, loss of exon 1 sequences may result in the potential loss of biochemical or biological characteristics that may be encoded by these sequences.
v-abl-mediated transformation
In vivo
Murine leukemias induced by A-MuLV are characterized by a short latency period, during which time lymphoblast infiltration of the marrow, meninges and lymph nodes occurs. No such infiltration has been observed in the thymus. The neoplastic tissue examined from infected animals is unusual in its appearance and growth characteristics when compared to neoplasms isolated from other virus-induced murine leukemias. AMuLV-infected animals would often show deformities in the skull, for example, as the proliferating cells spread rapidly to adjacent cranial structures (Rabstein et al., 1971; Siegler et al., 1972) . The presence of a normal thymus gland in animals with A-MuLVinduced leukemias suggests that cells other than T lymphocytes are the target tissues. Transplanted AMuLV-induced tumors were analysed for surface markers, and Ig heavy chain was observed on all the cells analysed (Premkumar et al., 1975) . The finding that A-MuLV tumor cell lines synthesize membrane bound IgM identified B-lymphocytes as the A-MuLV targets. This observation was confirmed in transformation studies in vitro (Sklar et al., 1974; Raschke et al., 1975; Rosenberg et al., 1975) .
Murine lymphoid tumors derived from A-MuLV infection are not polyclonal in origin despite the rapid onset of neoplastic disease in infected mice (Green et al., 1989) . In an effort to determine the additional genetic steps required for tumor formation induced by A-MuLV infection, investigators focused on a potential role for the p53 tumor suppressor gene. Loss or mutation of p53 sequences is observed in approximately 50% of A-MuLV induced lymphoid tumor cells (Thome et al., 1997) . The critical role for p53 in v-Ablinduced leukemia was confirmed by examining v-Abl transforming activity in p53-deficient or heterozygous mice. p53 null mice succumbed to A-MuLV induced leukemia with a rate almost twice that of either wild type or heterozygous animals (Unnikrishnan et al., 1999; Zou et al., 2000) . A-MuLV-infected primary lymphoid cells from p53 null mice escaped p53-mediated apoptotic crisis, whereas wild type (p53 +/+ ) and heterozygous (p53 +/7 ) infected cells did not. As predicted from this observation, establishment of v-Abl expressing p53 +/7 primary cells in culture was accompanied by loss of the remaining p53 allele. While loss of p53 contributes to v-Abl-induced leukemia by preventing apoptotic crisis in A-MuLV infected cells, the mechanism for wild type p53 activation in the apoptotic crisis is less clear. v-Abl-mediated p53-induced apoptosis is independent of both p21 cip-1 (Unnikrishnan et al., 1999) and p16 ink4a expression. p19Arf expression, however, is required for this process (Radfar et al., 1998; Unnikrishnan et al., 1999) . P19Arf-p53 signaling may regulate the v-Abl crisis checkpoint since this function is lost in both p53 null and p19 null cells (Radfar et al., 1998) .
Fibroblasts
In vitro A-MuLV encoded tyrosine kinase activity is required for transformation of cultured fibroblasts (Prywes et al., 1985) . Certain cultured fibroblastic lines expressing v-Abl, however, did not become transformed. Those cell lines, termed non-permissive, underwent cell cycle arrest and death following expression of the v-Abl protein (Ziegler et al., 1981; Renshaw et al., 1992) . Non-permissive NIH3T3 cells differ from their permissive counterparts by their p53 functions although the sequence of the p53 gene is normal in both lines. In permissive cells, p53 function is compromised. This was demonstrated by a failure of p53 protein accumulation, inability to induce cell cycle arrest and inability to induce p21 expression following DNA damage (Huang et al., 1996) . p53, however is not directly responsible for susceptibility to v-Abl-mediated transformation, since Human Papilloma Virus E6-mediated inactivation of p53 does not render resistant cells permissive (Cong et al., 1999b) . In contrast to these immortalized fibroblasts, primary mouse embryo fibroblasts (MEFs) can be rendered susceptible to v-Abl transformation by loss of either p53 or p19
Arf expression (Cong et al., 1999b) . This suggests that within certain cellular contexts p53 activates an apoptotic response to the expression of v-Abl tyrosine kinase. In the v-Ablmediated transformation process, loss of p53 function is necessary for relief from p53-induced cell cycle arrest or apoptosis.
Expression of v-Abl in transformation permissive cells activates numerous signaling cascades that result in cell transformation. Signal transduction pathways up-regulated following expression of v-Abl include Ras, Jak-Stat, JNK, and PI-3 kinase (Figure 2 ). vAbl transformation is Ras-dependent and can be blocked by interfering either with ras gene expression or with Ras protein function v-Abl mediated transformation SK Shore et al (Stacey et al., 1991) . Activation of Ras by v-Abl requires both kinase activity and localization of the vAbl gene product to the cell membrane (Prywes et al., 1985; Wong et al., 1995) . Although deletion of the majority of the Mo-MuLV-derived gag sequences has little effect on v-Abl transforming activity, the N- terminal 34 amino acids derived from p15 gag encode a myristylation signal (Prywes et al., 1983) . This posttranslational modification is required to localize v-Abl to the plasma membrane (Schultz and Oroszlan, 1984) . Accumulation of v-Abl protein at the plasma membrane brings v-Abl into proximity with the gene products that mediate cellular proliferation control, thereby initiating signal transduction pathways that culminate in transformation.
Activation of the Ras pathway may originate through a number of individual protein -protein interactions occurring at the plasma membrane. One such pathway is activated by a Phospho-tyrosine-independent association between the v-Abl SH2 domain and the adaptor protein Shc (Figure 2a ). Subsequent to this binding, Shc becomes phosphorylated on tyrosine by v-Abl. Tyrosine phosphorylated Shc then acquires the ability to bind Grb2/Sos, which results in activation of the Ras pathway (Raffel et al., 1996) . In addition to the v-Abl SH2 domain, the proline-rich stretch towards the Cterminus of v-Abl may also participate in Ras activation. This domain associates with several SH3-containing adaptor proteins including Crk, Nck and Grb2 (Ren et al., 1994) . Inactivation of the SH3 domains of these adaptor molecules by mutagenesis confirmed a role for both Crk and Grb2 in v-Abl signaling to Erk, while eliminating the participation of Nck (Tanaka et al., 1995) . p62Dok, a recently identified adapter molecule, is a known v-Abl substrate and this protein, when phosphorylated, binds to the Ras exchange protein RasGAP (Figure 2b (Cong et al., 1999a) . However, a related docking protein, DOKL, does function as a specific inhibitor for both v-Abl-induced Ras activation and transformation (Cong et al., 1999a) . The mechanistic differences between these two counter-regulatory Ras control points and their role in v-Abl transformation remains to be determined.
Increased c-Myc expression was one of the first downstream molecular characteristics to be identified in v-Abl transformed cells (Nepveu et al., 1985; Cleveland et al., 1989) . The requirement for c-myc expression in v-Abl transformation was confirmed using dominant negative constructs (Sawyers et al., 1992) . A pathway linking v-Abl to c-Myc through Ras was proposed by Zou et al. (1997) , validating prior vAbl transformation studies. Using both dominant negative and constitutively active constructs, both Ras and Raf1 were shown to be required for v-Abl induced c-myc up-regulation (Figure 2a) . Expression of c-myc was, in turn, dependent upon release of pocket protein bound E2F. As expected, increased activities of Cdk 2 and Cdk 4 were accompanied by hyperphosphorylation of the E2F-binding pocket proteins, pRb 105 , p107 and p130, thereby releasing transcriptionally active E2F. Overexpression of either p21 cip1 , or pRb inhibited E2F-dependent expression of the c-myc promoter, confirming the role of the Cdks in v-Ablmediated transformation pathways. While this dissection relied on transactivation of the c-myc promoter as the read-out, a subsequent study attempted to determine if the v-Abl-induced expression of c-myc was a specific effect, or if it reflected a general increase in E2F regulated gene transcripts. v-Abl expression does in fact lead to increased expression of additional E2F-responsive genes including DHFR, ribonucleotide reductase and cyclins E and A, all critical components for cell proliferation .
v-Abl-mediated signaling is not limited to the Rasdependent activation of the transcription factor E2F. v-Abl expression activates the c-fos promoter through both serum response (SRE) and TPA response elements (TRE) (Hori et al., 1990) . Cytoplasmic sequestration of the AP-1 inhibitor Grb4 by v-Abl may also contribute to the increased expression from SRE and TRE containing promoters (Jahn et al., 2001) . Unlike the c-myc promoter, SRE and TRE element activation is Rac dependent (Renshaw et al., 1996; Zou et al., 1997) (Figure 2c) . Dominant negative studies have been employed to determine the role of vAbl in activation of Rac, Erk and Jnk activity in SRE and TRE-regulated gene expression, and cell transformation (Renshaw et al., 1996) . Jnk and Erk2 activities are both increased by v-Abl expression (Raitano et al., 1995) and active v-Abl kinase results in increased levels of both c-fos and c-jun (Renshaw et al., 1992) . Increased AP-1 signaling, however, seems to be specific to fibroblasts since v-Abl expression in myeloid cells does not increase either c-fos or c-jun levels (Cleveland et al., 1989) . Further, A-MuLV has been shown to induce pre-B cell leukemias effectively in fos null mice (Saez et al., 1995) .
Hematopoietic cells
As was noted earlier, v-abl transforms hematopoietic cells isolated from a number of tissues including spleen, fetal liver and bone marrow in vitro (Sklar et al., 1974; Raschke et al., 1975; Rosenberg and Baltimore, 1976; Rovera et al., 1987) . Analysis of the transformed cells arising from these infected cultures revealed that the target cell for A-MuLV transformation is the pre-B cell. In vivo, B-lymphocytic (Whitlock et al., 1983) , erythroid (Waneck et al., 1986) and monocytic (Keller et al., 1990) maturation is unaffected by v-Abl expression.
In vitro, A-MuLV infection of both myeloid and mast cells (Raschke et al., 1978; Cook et al., 1985) relieves their IL-3 dependence without affecting IL-3 release into the medium, IL-3 RNA transcription or the number of IL-3 cell-surface receptors. Erythroid cells are dependent upon erythropoietin for both growth and differentiation and A-MuLV is also able to produce cytokine-independence (Waneck et al., 1986) . Waneck et al. (1986) compared A-MuLV and v-Ha-ras-mediated erythroid cell transformation, and found that both viruses infect the same target cells, but v-Abl mediated transformation SK Shore et al v-Ha-ras infected cells remain erythropoietin dependent. Interestingly, A-MuLV can substitute for or supersede the requirement for erythropoietin in v-Haras infected cells (Waneck et al., 1986) . Not surprisingly pre-B cells, the predominant target of A-MuLV transformation, also become IL-3 independent following A-MuLV infection (Mathey-Prevot et al., 1986) . In vitro assays showed this to be neither autocrine in nature nor due to the activation of the c-myc gene. These studies show that a common step associated with diverse cytokine-mediated signal transduction pathways may be A-MuLV sensitive. Cells which become factor independent still show a responsiveness to the factor demonstrating the integrity of the pathway (Kiproes et al., 1988) . Studies with an IL-3 dependent myeloblastic cell line, 32Dcl3, revealed that expression of v-Abl oncogene in these cells not only results in the appearance of IL-3-independent cell lines, but also results in a block to GCSF-induced terminal differentiation (Rovera et al., 1987) . However, when the cells are stimulated with G-CSF prior to infection, they become refractory to A-MuLV transformation and respond normally to G-CSF by undergoing terminal differentiation. These results demonstrate that v-Abl can only transform immature myeloid cells and activation of differentiation pathways in these cells results in a resistance to v-Abl-mediated transformation.
Signal transduction pathways activated by v-Abl
The ability of v-Abl to transform both fibroblasts and hematopoietic cells suggests that a common pathway controlling the proliferation of both cell types can be affected by v-Abl expression. Another possibility, that v-Abl has the ability to activate multiple cell-specific signaling pathways, may also exist. Two common pathways affected by v-Abl expression are the Ras and c-myc pathways (Figure 2a ). Fibroblast and hematopoietic cell transformation both require the activation of these pathways . Over the past several years dedicated work from several groups has established that hematopoietic cell growth and differentiation is mediated by a group of soluble factors known as the cytokines (Kishimoto et al., 1994; Hunter, 1993; Stahl and Yancopoulos, 1993; Taniguchi, 1995) . Cytokines bind to their cognate receptors and mediate intracellular signal transduction events that result in the modulation of gene expression. Current models suggest that interaction of cytokines with their receptors leads to the activation of a group of tyrosine kinases termed Janus, or JAK kinases, which mediate the phosphorylation of cytokine receptors. The phosphorylated tyrosine residues on the receptors serve as docking sites for a group of transcription factors termed STATs (Signal transducers and activators of transcription). STATs are, in turn, phosphorylated by JAKs or Src kinases that are recruited to the cytokine receptors. Phosphorylation of STATs results in their dimerization, facilitating their transport to the nucleus which then results in the transcriptional activation of genes that are essential for cell growth and differentiation (Darnell et al., 1994) .
Analogous to receptor tyrosine kinase signaling in fibroblasts, expression of v-Abl is sufficient to activate the JAK/STAT pathway in the absence of cytokines. Cytokine-independent activation of JAKs results in the activation of STAT transcription factors. v-Abl expression renders cells factor-independent by constitutive activation of the Jak 1 and 3 which in turn mediate the phosphorylation of STATs, that are otherwise activated by the cytokines IL-3, -4 and -7 (Danial et al., 1995) . In BaF3 pre-B cells, v-Abl and Jak1/3 are associated constitutively, and activation of v-Abl kinase activity increases the binding, suggesting a phosphotyrosine-induced stabilization (Danial et al., 1995) . The Jak association domain lies within the Cterminus of v-Abl, overlapping the c-Abl DNA binding domain . The Abl Cterminus is responsible both for the ability to transform lymphoid cells and to abrogate cytokine dependence (Mathey-Prevot and Baltimore, 1988) . Deletion of the Jak1 association domain within v-Abl compromises its ability to render cells cytokine independent. Conversely, a kinase-inactive Jak1 coexpressed with v-Abl leads to diminished phosphorylation of STATs (Danial et al., 1998) . The result of the activated Jak and v-Abl kinases is an increase in activated phospho-STAT-1,-3 and -5 independent of cytokine action. One of the interesting observations made previously has been the frequent isolation of truncated v-Abl mutants retaining fibroblast transforming activity with poor transforming activity in lymphoid cells . One possible explanation is a reduction in Jak binding by these truncated Abl gene products, thus reducing the amount of cytokine-independent of STAT-mediated gene transcription. This carboxy terminal region of Abl has also been found to cooperate with Ras . The individual contribution of these two signal pathways and their relationship with the Cterminus has yet to be resolved.
Hematopoietic cell transformation requires a survival signal in addition to a proliferation signal. Because apoptosis hinges on the balance between pro-and antiapoptotic signals, v-Abl expression must exert an effect on cell survival to attain cell transformation. This has, in fact, been found using a temperature sensitive v-abl allele (ts-v-Abl). Expression of ts-v-Abl in cells at permissive temperatures leads to transformation. Shifts in growth conditions to non-permissive temperatures result in cells undergoing apoptosis (Kipreos and Wang, 1988; Engleman and Rosenberg, 1990; Chen and Rosenberg, 1992; Owen et al., 1993; Chen et al., 1994) . Numerous signaling pathways have been implicated in v-Abl induced survival. Early studies have found that Phosphotidyl Inositol-3-Kinase (PI3-kinase) was activated in v-Abl transformed cells, resulting in an increase in phospholipid second messengers in these cells (Varticovski et al., 1991) v-Abl mediated transformation SK Shore et al (Figure 2d ). This is functionally significant since inhibition of PI-3-kinase with LY294002 inhibits the v-Abl anti-apoptotic activity (Tang et al., 2000) . Using cells which express ts-v-Abl, Tang et al. (2000) also found that Akt activity was increased at permissive temperatures, but was responsible for only a limited effect on v-Abl induced survival. The mechanism responsible for v-Abl-induced activation of PI3-kinase is not yet known. The mechanism may be direct (Varticovski et al., 1991; Tang et al., 2000) or it may rely on other activated intermediates including JAKs (Winston and Hunter, 1995; Burfoot et al., 1997) and Ras (Kauffman-Zeh et al., 1997) (Figure 2b ). Additional anti-apoptotic molecules associated with v-Abl are two members of the BCL-2 family, Bcl-2 and Bcl-x L . Both gene products are anti-apoptotic and each is up-regulated in certain v-Abl transformed cells. In both pre-B and myeloid factor-dependent cells v-Abl expression stabilizes Bcl-2 levels when cytokines are withdrawn (Zhu et al., 1996; Banerjee and Rothman, 1998) . The Bcl-x L gene product levels are also increased in v-Abl transformed cells (Chen et al., 1997; Banerjee and Rothman, 1998) . One possible mechanism responsible for elevated Bcl-x L levels is the activation of protein kinase C (PKC) (Chen et al., 1997) . PKC was shown earlier to promote cell survival in a v-Abldependent manner since inhibition of PKC resulted in a loss of cell viablity (Evans et al., 1995) . It is also possible, but untested, that Akt phosphorylation of pro-apoptotic Bad protein may increase the levels of free Bcl-x L , thus inhibiting apoptosis.
The v-Abl pro-apoptotic effect may involve NF-kB. During studies on the v-Abl-induced arrest of B-cell differentiation it was found that v-Abl negatively regulates NF-kB transcription factors by an unidentified post-translational mechanism (Klug et al., 1994) . NF-kB produces multiple biological effects, affecting cell proliferation, survival and death (Foo and Nolan, 1999; Gutteridge et al., 1999; Hinz et al., 1999) . The NF-kB anti-apoptotic effect blocks death receptorinduced apoptosis (Beg and Baltimore, 1996; van Antwerp et al., 1996) but it also can cooperate with p53 mediated apoptosis (Ryan et al., 2000) . The consequences of NF-kB negative regulation by v-Abl have not been formally addressed but one study reported v-Abl inhibition of Fas-induced apoptosis (McGahon et al., 1995) . Alternatively the inhibition of p53-mediated cell death by the negative regulation of NF-kB by v-Abl could be an important step in overcoming apoptotic crisis during transformation (Ryan et al., 2000) .
Transformation by v-Abl involves multiple signaling pathways that may exhibit cell specificity. Specific perturbations in pathways have been identified, yet the specific contribution of each to transformation is only beginning to be understood. v-Abl transformation is a result of enforced proliferation and cell survival by this tyrosine kinase. A critical step is the localization of this potent enzyme at the inner surface of the cell membrane where it can subvert highly regulated signal complex formation due to its deregulated tyrosine kinase activity. v-Abl signaling mimics, to some degree, a number of cytokines, including IL-3 and IL-7. Individually, however, these cytokines fail to induce the same wide spectra of signals as those originating from v-Abl (Banerjee and Rothman, 1998). Despite the enormous strides made in characterizing v-Abl-induced signal transduction pathways, no profile representing regulated genes has yet been identified. Questions of cause and effect also remain. Which signals are required and which are consequences of v-Abl transformation? How does v-Abl overcome regulation of the activated pathways? For example, how is the negative feedback on Jak activity by STAT induced transcription of SOCS overridden? The finding of the virus from a single mouse has led to an enormous increase in our knowledge of cellular transformation and no end appears to be in sight.
